Fig. 2: CART expansion, cytokine changes, and CRS in the patients. | Cell Discovery

Fig. 2: CART expansion, cytokine changes, and CRS in the patients.

From: Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic malignancy

Fig. 2

Patients (as numbered in Table 1) with refractory or relapsed ALL, CLL, Lymphoma, or MM were enrolled and treated with anti-CD19 or anti-BCMA CART secreting anti-IL6 scFv and IL1RA. After CART infusion, patients were monitored for clinical signs of CRS and examined for clinical response of tumor remission. a Changes of IFNG, IL6, IL1RA, IL1B, and CAR vector copies in blood. b Plot of IFNG peak levels versus the IL6 concentration at the time of IFNG peak during CRS. c Plot of IFNG peak levels versus the IL1B concentration at the time of IFNG peak during CRS. d The relationship between CRS gradings and IFNG peaks, or IL6, IL1B, CRP, and Ferritin levels at the time of IFNG peaks during CRS.

Back to article page